HC Wainwright Issues Positive Forecast for Evotec (NASDAQ:EVO) Stock Price

Evotec (NASDAQ:EVO) had its price target raised by equities researchers at HC Wainwright from $4.00 to $5.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright‘s target price would indicate a potential upside of 181.69% from the stock’s current price.

Several other brokerages have also recently commented on EVO. Weiss Ratings cut shares of Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 25th. TD Cowen lowered shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price objective on the stock. in a research note on Wednesday, July 15th. Finally, Berenberg Bank cut shares of Evotec from a “buy” rating to a “hold” rating in a report on Thursday, July 16th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $3.50.

Evotec Stock Performance

Shares of EVO opened at $1.77 on Friday. The stock has a 50-day moving average of $1.62 and a two-hundred day moving average of $2.49. Evotec has a one year low of $1.33 and a one year high of $3.87. The company has a quick ratio of 2.21, a current ratio of 2.33 and a debt-to-equity ratio of 0.62.

Institutional Investors Weigh In On Evotec

An institutional investor recently raised its position in Evotec stock. Optiver Holding B.V. lifted its position in shares of Evotec AG (NASDAQ:EVO) by 598.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 283,576 shares of the company’s stock after purchasing an additional 242,973 shares during the quarter. Optiver Holding B.V. owned 0.08% of Evotec worth $709,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 5.81% of the company’s stock.

Trending Headlines about Evotec

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: Q3 adjusted EBITDA loss narrowed to €1.6 million, while reported revenue of €164.9 million and an EPS loss of $0.11 beat analyst estimates. The company also reaffirmed its FY2026 guidance. Evotec Q3 and nine-month results
• Positive Sentiment: Evotec reported 24% growth in D&PD base-business net sales and won a Vertex manufacturing mandate, supporting the case for commercial momentum. Vertex manufacturing mandate
• Neutral Sentiment: Management said restructuring is progressing, but the Redmond expansion may create a gap before added capacity contributes revenue. The timing and pace of the ramp could affect near-term performance. Redmond expansion revenue gap
• Negative Sentiment: Nine-month revenue fell to €465.0 million from €477.4 million at constant exchange rates, and adjusted EBITDA remained negative. Evotec also tempered and pushed out medium-term goals, including lowering its 2030 revenue target. Evotec cuts 2030 revenue target
• Negative Sentiment: RBC maintained a cautious view and cut its price target to €5, adding to concerns about the reduced longer-term outlook. RBC target and Vertex mandate

Evotec Company Profile

Evotec SE is a Germany-based biotechnology company that provides drug discovery and development services to pharmaceutical, biotechnology and academic research organizations. The company combines scientific expertise, proprietary technologies and integrated research platforms to identify and advance potential medicines across multiple therapeutic areas, including neuroscience, oncology, metabolic disease, infectious disease and inflammation.

Evotec’s activities span early-stage target identification, compound screening, medicinal chemistry, pharmacology, preclinical research and selected clinical development services.